47 completed, 33 unknown, 10 recruiting, 8 not yet recruiting. 103 Phase 2, 22 Phase 1, 21 Phase 3.
Follow Control group: new trials by email Literature Review of Control group trials Research Report on Control group
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation DN022150+AG( Stage I ）, DN022150+AG（Stage II）, placebo+AG（Stage II） - Pancreatic Cancer, Pancreatic Carcinoma | Phase 2 / Phase 3 | Not yet recruiting | Jiangxi Kvvit Pharmaceutical Co., Ltd. | 465 | 2027-06-06 | 2026-06-18 |
| SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease, NAFLD | Phase 2 | Not yet recruiting | Justin Ryder | 40 | 2027-05-01 | 2026-01-20 |
| To Evaluate the Safety and Efficacy of Hemay5394 in Patients With Mild to Moderate Atopic Dermatitis Hemay5394 group, Control group - Safety, Efficiency | Phase 2 | Not yet recruiting | Hemay Pharmaceutical PTY. LTD. | 90 | 2026-11-01 | 2026-10-16 |
| Eparlitozoviril as Adjuvant Therapy for Resectable HCC With MVI eparlitozoviril, Control group - HCC - Hepatocellular Carcinoma | Phase 2 | Active not recruiting | Tianjin Medical University Cancer Institute and Hospital | 60 | 2026-06-12 | 2026-06-18 |
| hUC-MSC-Exosomes for T2DM - Safety & Efficacy exosomes treatment group, control group - Type 2 Diabetes Mellitus (T2DM) | Phase 1 / Phase 2 | Recruiting | Peking University First Hospital | 66 | 2026-06-05 | 2026-07-09 |
| SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS SHR2554/AZA + Overlapped TBF, mBUCY conditioning regimen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Soochow University | 160 | 2026-06-01 | 2026-05-01 |
| Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria Experimental Group, Control group - Rectal Cancer | Phase 2 / Phase 3 | Recruiting | The First Hospital of Jilin University | 212 | 2026-02-23 | 2026-04-01 |
| Sevoflurane Sedation in Patients With Septic Shock Sevoflurane, Control Group - Shock, Septic | Phase 2 | Not yet recruiting | University of Zurich | 153 | 2026-01-01 | 2025-04-01 |
| Gluma Compared With Bonding Agent for Post-operative Sensitivity Following Composite Restorations Drug/Agent: Gluma Desensitizer, Drug/Agent: No desensitizer (Control) - Post-operative Sensitivity, Dentin Hypersensitivity | Phase 2 / Phase 3 | Not yet recruiting | Beenish Hassan | 60 | 2025-12-01 | 2025-09-23 |
| Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day., DHEA plus folic acid 400mcg per day, control group - Infertility, Infertility (IVF Patients) | Phase 2 / Phase 3 | Recruiting | Beni-Suef University | 165 | 2025-10-10 | 2026-01-07 |
| A Study of Regorafenib Combined With Envafolimab for Metastatic Gastrointestinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard Treatment regorafenib combined with envafolimab, Control Group - Metastatic Gastrointestinal Stromal Tumors (GIST) | Phase 2 | Not yet recruiting | Peking University | 100 | 2025-07-30 | 2025-07-31 |
| Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease Empagliflozin 10 MG, Placebo Oral Tablet - Non-Alcoholic Fatty Liver Disease | Phase 2 | Recruiting | Justin Ryder | 40 | 2025-04-10 | 2026-01-21 |
| Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia TmBU conditioning Regimen, mBUCY conditioning regimen - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 48 | 2025-01-30 | 2026-04-23 |
| A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment VUM02 Injection (UC-MSCs)+BAT, The control group with Best Available Therapy (BAT) - Steroid-refractory Acute Graft-versus-host Disease | Phase 1 / Phase 2 | Not yet recruiting | Wuhan Optics Valley Vcanbiopharma Co., Ltd. | 149 | 2025-01-01 | 2024-11-06 |
| Dexmedetomidine and Vasopressin in Septic Shock DEX-PRESSIN, Standard of Care - Sepsis, Septic Shock | Phase 2 | Unknown | Mansoura University | 260 | 2024-06-01 | 2024-03-12 |
| Efficacy and Safety of Fractional CO2 Laser Combined With Intralesional Insulin, Botulinum Toxin or Triamcinolone Acetonide in the Treatment of Keloid: A Clinical, Dermoscopic and Immunohistochemical Study. Insulin group, Botulinum toxin group, Triamcinolone acetonide group - Keloid | Phase 1 / Phase 2 | Unknown | Assiut University | 45 | 2024-05-01 | 2024-01-30 |
| Further MT for Antibiotic-Resistant Bacterial Colonization Microbiome Therapeutic, Placebo - Intestinal Multi-drug Resistant Organism Colonization | Phase 2 | Recruiting | Emory University | 40 | 2024-04-25 | 2026-05-06 |
| SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19) SHEN211 Tablets, Placebo for SHEN211 Tablets - COVID-19 | Phase 2 | Unknown | JKT Biopharma Co., Ltd. | 30 | 2024-04-01 | 2024-03-04 |
| Platelet Rich Plasma Combined With Human Umbilical Cord Mesenchymal Stem Cells for Stage 3 and 4 Stress Injury Platelet-rich plasma (PRP) combined with human umbilical cord mesenchymal stem cells (huMSCs), Control group - Pressure Injuries - Stage 3, Pressure Injuries - Stage 4 | Phase 1 / Phase 2 | Unknown | Liaocheng People's Hospital | 40 | 2024-02-29 | 2024-03-12 |
| Validity of Ozonated Olive Oil Gel Versus Injectable Bone Graft Immediate implant placement, β-tricalcium phosphate Injectable Bone Graft, Ozonated olive oil gel - Dental, Implant Osseointegration | Phase 2 | Completed | Suez Canal University | 16 | 2023-12-10 | 2026-01-26 |
Showing 20 of 103. Sign in to see all of them.
COVID-19 (6) · Heart Failure (3) · Non-alcoholic Fatty Liver Disease (3) · Pain, Postoperative (3) · Periodontitis (3) · Stroke (3) · Breast Neoplasms (2) · Dental Caries (2) · Diabetes Mellitus (2) · Leukemia, Myeloid, Acute (2) · Multiple Sclerosis (2) · Neoplasms (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Sepsis (2) · Shock, Septic (2)
Assiut University (3) · National Cancer Institute, Egypt (3) · Capital Medical University (2) · Ever Supreme Bio Technology Co., Ltd. (2) · Justin Ryder (2) · SVS Institute of Dental Sciences (2) · The First Affiliated Hospital of Soochow University (2) · ASST Santi Paolo e Carlo (1) · Abdelrady S Ibrahim, MD (1) · Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran (1) · AdvanceCor GmbH (1) · Alhasan Mujtaba Abdul-Wahid (1) · Andrews Research & Education Foundation (1) · Aristotle University Of Thessaloniki (1) · Asociación para Evitar la Ceguera en México (1)
China (20) · Egypt (14) · United States (13) · Taiwan (5) · India (4) · Spain (4) · France (3) · Mexico (3) · Australia (2) · Brazil (2) · Canada (2) · Iran (2) · Italy (2) · Pakistan (2) · South Korea (2)
Ehab H Shaker, MD (3) · Justin Ryder, PhD (2) · Woei C Shyu (2) · Abubaker M Elnashar, MD (1) · Adam W Anz, MD (1) · Ahmed Mohamed El Rawdy, Professor (1) · Alhasan Mujtaba, BCPS (1) · Amir Moeintaghavi, DDS.,Ms. (1) · Assad H Kata, Ph.D (1) · Bojan Vrtovec, MD, PhD (1) · Carlos CP Oliveira (1) · Carlos Tene, DS (1) · Chin-Ying Chen, MD, MHSc (1)
PMID 10434461, PMID 10459293, PMID 11530753, PMID 12141594, PMID 14640675, PMID 15026283, PMID 15110326, PMID 15362760, PMID 15701582, PMID 16219273, PMID 17307530, PMID 17450108, PMID 18254095, PMID 18566668, PMID 19063954, PMID 19128748, PMID 19572819, PMID 20148633, PMID 20963840, PMID 21232112, PMID 21813309, PMID 21873560, PMID 22369555, PMID 22808958, PMID 23234752, PMID 23543702, PMID 23635074, PMID 24431901, PMID 24753708, PMID 24815768, PMID 25046256, PMID 25346899, PMID 25835756, PMID 25911280, PMID 25934946, PMID 26325247, PMID 26797689, PMID 26924470, PMID 27558893, PMID 28149281, PMID 28870191, PMID 28880460, PMID 29234356, PMID 29785539, PMID 30048006, PMID 30525951, PMID 30864096, PMID 31307503, PMID 31600109, PMID 31980156
R01AA014270 (1), R01HD074944 (1), U19AI066738 (1), U54CK000601 (1)